



Cell Therapy Innovation 360°

From basic research to patient delivery

PROGRAMME

WEDNESDAY 19TH
AND
THURSDAY 20TH JANUARY 2022

3RD EDITION

www.cti360congress.com



OLIMPE
CRÉATEUR DE VALEUR EN IMMUNOLOGIE

 LA REVUE
Immunité & Cancer

Mieux comprendre pour mieux traiter

Wednesday 19th January 2022

10³⁰ - 10⁴⁰

WELCOME & INTRODUCTION

Gilles Salles (New York, USA)
Jean-Yves Blay (Lyon, France)

10⁴⁰ - 11¹⁰

KEYNOTE LECTURE

CAR T-CELL DELIVERY: EXPLORING NEW METHODS

Moderator: Gilles Salles (New York, USA)
Speaker: Crystal Mackall (Stanford, USA)

11¹⁰ - 12²⁵

CAR T-CELLS IN LYMPHOMA, MYELOMA & ALL: LATEST CLINICAL DATA

Moderator: Susana Rives (Barcelona, Spain)
Speakers: Ulrich Jäger (Vienna, Austria)
Nikhil Munshi (Boston, USA)
André Baruchel (Paris, France)

12²⁵ - 13²⁵

LUNCH BREAK

13²⁵ - 14²⁵

INDUSTRY SATELLITE SYMPOSIUM



14²⁵ - 15¹⁰

OPTIMAL TREATMENT SEQUENCING: THE PLACE OF HSCT, BITES & CAR T-CELLS IN DLBCL & MYELOMA

Moderator: Jacques-Olivier Bay (Clermont-Ferrand, France)
Speakers: Guillaume Cartron (Montpellier, France)
Philippe Moreau (Nantes, France)

Wednesday 19th January 2022

15¹⁰ - 15⁵⁵

MYELOMA: CLINICAL CASE

Supported by



Speakers: Lionel Karlin (Lyon, France)
Philippe Moreau (Nantes, France)

15⁵⁵ - 17⁰⁵

REAL-LIFE EXPERIENCE

The DESCART Registry

Speaker: Roch Houot (Rennes, France)

From patient selection to infusion

Speakers: Catherine Thieblemont (Paris, France)
Susana Rives (Barcelona, Spain)

Toxicity management in multiple myeloma

Speaker: Nikhil Munshi (Boston, USA)

17⁰⁵ - 17²⁵

BREAK

17²⁵ - 18²⁵

INDUSTRY SATELLITE SYMPOSIUM

Celgene |  Bristol Myers Squibb[™]
Company

18²⁵ - 18⁵⁵

CAR T-CELLS: WHAT HAS BECOME OF LONG-TERM SURVIVORS?

Moderator: André Baruchel (Paris, France)

18⁵⁵

CONCLUSION

Thursday 20th January 2022

09⁰⁰ - 09³⁰

HOW CAN CAR-T EFFICACY BE IMPROVED?

Moderator: Emmanuel Bachy (Lyon, France)
Speaker: Stanley Riddell (Seattle, USA)

09³⁰ - 10³⁰

INDUSTRY SATELLITE SYMPOSIUM

Celgene |  Bristol Myers Squibb[™]
Company

10³⁰ - 10⁵⁰

BREAK

10⁵⁰ - 11¹⁰

HOW DO ENGINEERED T-CELLS KILL THEIR TARGET?

Moderator: Roch Houot (Rennes, France)
Speaker: Philippe Bousso (Paris, France)

11¹⁰ - 12¹⁰

CELLULAR THERAPIES: WHAT DOES THE FUTURE HOLD?

Speakers: Katy Rezvani (Houston, USA)
Justin Eyquem (San Francisco, USA)
Michael Hudecek (Würzburg, Germany)

12¹⁰ - 13⁰⁰

LUNCH BREAK

13⁰⁰ - 13⁴⁰

BIOTECH PRESENTATIONS



Thursday 20th January 2022

INDUSTRY SATELLITE SYMPOSIUM



13⁴⁰ - 14⁴⁰

CAR T-CELLS IN SOLID TUMORS: WHAT IS NEW?

Moderator: Antoine Italiano (Bordeaux, France)

Speakers: Jean-Yves Blay (Lyon, France)

Christopher Klebanoff (New York, USA)

14⁴⁰ - 15¹⁰

15¹⁰ - 15⁵⁰

**CAR T-CELLS IN HEMATOLOGIC MALIGNANCIES:
NEW CHALLENGES**

Speakers: Gilles Salles (New York, USA)

André Baruchel (Paris, France)

15⁵⁰ - 16⁵⁰

**REGIONAL ORGANIZATION IN FRANCE:
MANAGING THE INCREASE IN INDICATIONS FOR
CAR-T THERAPY**

Moderator: Corinne Haioun (Créteil, France)

Speakers: Emmanuel Bachy (Lyon, France)

Krimo Bouabdallah (Bordeaux, France)

Nicolas Boissel (Paris, France)

Xavier Leleu (Poitiers, France)

16⁵⁰

CONCLUSION



Cell Therapy Innovation 360°

From basic research to patient delivery

CHAIRMEN

Prof. Gilles Salles Hematologist

Memorial Sloan Kettering
Cancer Center
New York, USA



Prof. Jean-Yves Blay Oncologist

Université Claude Bernard Lyon 1
Centre Léon Berard
Lyon, France



SCIENTIFIC COMMITTEE

Prof. Bertrand Arnulf (Hôpital Saint-Louis, Paris, France)

Prof. Emmanuel Bachy (Hospices Civils, Lyon, France)

Prof. André Baruchel (Hôpital Robert Debré, Paris, France)

Prof. Jacques-Olivier Bay (CHU, Clermont-Ferrand, France)

Prof. Nicolas Boissel (Hôpital Saint-Louis, Paris, France)

Prof. Guillaume Cartron (CHU, Montpellier, France)

Prof. Roch Houot (CHU, Rennes, France)

Prof. Ulrich Jäger (Medical University, Vienna, Austria)

Prof. Véronique Minard (Gustave Roussy, Villejuif, France)

Dr. Susana Rives (Hospital Sant Joan de Déu Barcelona,
Esplugues de Llobregat, Spain)